Novartis alleges Alembic infringed patent in US ANDA dispute over Kisqali
MLex Summary: Novartis Pharmaceuticals and Astex Therapeutics filed a patent infringement suit against Alembic Pharmaceuticals in the District of New Jersey, opposing Alembic’s Abbreviated New Drug Application (ANDA) to sell a...To view the full article, register now.
Already a subscriber? Click here to view full article